Natural protection against HIV-1 infection provided by HIV-2.
Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.
Travers
K
K
Department of Cancer Biology, Harvard School of Public Health, Boston, MA 02115, USA.
Mboup
S
S
Marlink
R
R
Guèye-Nidaye
A
A
Siby
T
T
Thior
I
I
Traore
I
I
Dieng-Sarr
A
A
Sankalé
J L
JL
Mullins
C
C
D016915:AIDS Vaccines; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D015986:Confounding Factors, Epidemiologic; D003429:Cross Reactions; D000939:Epitopes / Q000276:immunology; D005260:Female; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006679:HIV Seropositivity; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D015498:HIV-2 / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007113:Immunity, Innate; D015999:Multivariate Analysis; D011446:Prospective Studies; D012044:Regression Analysis; D012675:Senegal; D011477:Sex Work; D014774:Virulence
D016915:AIDS Vaccines; D000939:Epitopes; D015488:HIV Antigens